APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study

Yan Du1,2, Xiang Tao1,3, Jing Wu1,3, Huandi Yu1,3, Yinhua Yu1,3 and Hongbo Zhao1,3*

Abstract

**Background:** Ovarian cancer is a heterogeneous disease with a high degree of genomic instability, pro-/antitumor immunity and inflammation, and remains the most lethal gynecologic cancer worldwide. APOBEC3B, a member of the AID/APOBEC family, is part of the innate immune system which plays a key role in combating exogenous infection especially viral infection. Studies have shown that APOBEC3B expression is elevated in a variety of cancer tissues and cell lines, and plays a prominent role in the genesis and evolution of various cancers. However, the clinical relevance of APOBEC3B in ovarian cancer needs to be further investigated. The current study aimed to evaluate the predictive value of APOBEC3B in ovarian cancer clinical outcome, and to explore possible molecular mechanisms contributing to ovarian cancer progression.

**Methods:** The expression of APOBEC3B in biopsy tissue specimens from 88 ovarian cancer patients was examined using immunohistochemistry. In addition, ovarian cancer cell lines were transfected with APOBEC3B siRNA or pLenti-APOBEC3B construct. Western blotting and SRB assay were performed to explore the role of APOBEC3B in ovarian cancer.

**Results:** Patients were followed for a median of 74.77 months following the time of surgery. Forty-two patients had died, 5 had relapsed but were still alive at the end of study, and 41 patients remained alive and had no recurrence. Over-expression of APOBEC3B was associated with advanced FIGO stage and elevated CA125 (both p< 0.05). Univariate analysis result showed that histological subtype, FIGO stage, intravascular tumor thrombus, CA125 and APOBEC3B expression were associated with overall survival and disease-free survival of ovarian cancer patients. Multivariate analysis result showed that higher APOBEC3B expression were an independent prognostic factor to predict both worse overall survival (hazard ratio: 5.18, 95% confidence interval: 1.40–11.95, p = 0.003) and disease-free survival (hazard ratio: 4.23, 95% confidence interval: 1.60–11.17, p = 0.004) of ovarian cancer patients. Furthermore, knockdown of APOBEC3B expression in ovarian cancer cells caused an increase in cell line viability.

**Conclusions:** APOBEC3B expression is an independent prognostic factor in ovarian cancer patients. Knockdown of APOBEC3B expression affects ovarian cancer viability.

**Keywords:** APOBEC3B, Expression, Ovarian cancer, Survival, Viability

*Correspondence: zhaohongbo01@sina.com
1 Obstetrics and Gynecology Hospital, Fudan University, 419 Fangxie Rd, 200011 Shanghai, People’s Republic of China
Full list of author information is available at the end of the article

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Ovarian cancer is one of the most common gynecologic cancer among women and the most lethal gynecologic malignancy worldwide [1]. There were estimated 238,700 new cases of and 151,900 deaths due to ovarian cancer in 2012 [1]. In China, ovarian cancer burden will stay stable due to the aging population [2]. The etiology of ovarian cancer remains unclear. Epidemiological studies have shown that several factors, including family history, personal history of breast cancer, menstrual and reproductive factors, obesity, hormone therapy [3], inflammatory background [14], and autoimmunity disorders with inflammatory background [14]. Another study showed that APOBEC3B overly expressed in the majority of ovarian cancer cell lines and high-grade primary ovarian cancers. In addition, it also showed that APOBEC3B expression positively correlated with total mutation load as well as elevated levels of transversion mutations [15]. However, the clinical relevance of APOBEC3B in ovarian cancer needs to be further investigated. The current study aimed to evaluate the predictive value of APOBEC3B in ovarian cancer prognosis, and to explore the oncogenic role of APOBEC3B in ovarian cancer.

Materials and methods

Study population

This retrospective cohort study was conducted at the Obstetrics and Gynecology Hospital of Fudan University in Shanghai, China. During May 2006 to November 2008, patients with newly diagnosed sporadic ovarian cancer were selected. The study protocol was approved by the institutional review board of the hospital (Reference Number: 2018-24). Written informed consent was obtained from all participants.

Follow-up after surgical treatment

Clinical data and histopathologic data were collected from patients’ clinical and pathologic records. Follow-up was started 6 months after the surgery. Follow-up was performed by examinations every 3 months on an outpatient basis and/or by telephone calls according to our standard epidemiologic protocol.

TMA construction and immunohistochemistry

Tissue microarrays (TMAs) containing the specimens were obtained from the Tissue Bank of Obstetrics and Gynecology Hospital of Fudan University. Formalin-fixed, paraffin blocks of 112 ovarian cancer patients were retrospectively collected. Each specimen has the information of age, laterality, histology, and Federation of Gynecologists and Obstetricians (FIGO) stage at surgery. Before construction of TMA, hematoxylin and eosin (HE) stained slides from the blocks were reviewed to circle the interested region for coring. A 1-mm-diameter core in the circling region was released with a needle from each block, arrayed, and re-embedded in a recipient block. For standardization between different recipient blocks, in-cohort controls of the cores from eight specimens were presented on every array-block. To ensure representativeness, there were 2–3 cores for each patient on the array-block. After TMA construction, a HE section of the recipient block was reviewed to confirm that the interested region was contained in the cores. TMA cutting was performed and all finished slides were dipped...
in paraffin for preservation at 4 °C before immunohistochemistry assays.

The expression of APOBEC3B in each pretreatment biopsy tissue specimen was examined using immunohistochemistry according to previous protocol [16]. Briefly, the de-paraffinized sections were incubated with 20% goat serum for 30 min to block non-specific binding and were then incubated with primary antibodies against APOBEC3B (Abcam, Cambridge, UK, 1:100) at 4 °C overnight followed by anti-rabbit secondary antibody for 1 h at 37 °C. Bound antibody was then visualized using the EnVision™ Detection Systems (Dako, Glostrup, Denmark). Scoring the intensity of immunostaining was done semiquantitatively, and immunostaining was scored based on the percentage of the stained tumor cells: 0–10% as negative (−), 11–25% as slightly positive (+), 26–50% as moderately positive (++) and 51–100% as strongly positive (+++), respectively [17]. Those scores were then categorized into lower expression (− and +) and higher expression (++) for analyses. All specimens were analyzed independently by two observers (YD and HZ) who were blinded to the clinical information. There was close agreement (>90%) among the two investigators. Disagreements were resolved by consensus.

Reagents and antibodies
Monoclonal antibodies to APOBEC3B and GAPDH were obtained from Abcam (Abcam, Cambridge, UK). Secondary antibodies conjugated with horseradish peroxidase (HRP) were purchased from Jackson ImmunoResearch Laboratories (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Human pLenti-APOBEC3B construct was obtained from Asia-Vector Biotechnology (Asia-Vector Biotechnology, Shanghai, China).

Cell lines and culture
The four human ovarian cancer cell lines, A2780, HO-8910PM, SKOV3, and HEY were obtained from MD Anderson Cancer Center and the original source being the American Type Culture Collection (ATCC) (Manassas, VA, USA). All cell lines were cultured in 1640 complete medium supplemented with 10% FBS in 5% CO2 at 37 °C.

Transfection of siRNA and pLenti-APOBEC3B construct
All cells were seeded in 60 mm dishes at a density of 2 × 105/well, and transfected with APOBEC3B siRNA or pLenti-APOBEC3B construct using Lipo 2000 reagent according to the manufacturer’s instructions. The siRNAs targeting APOBEC3B and scrambled siRNA were synthesized and purified by RioBio Co. (RioBio Co., Guangzhou, China). At 48 h post-transfection, the cell pellets were collected for western blotting analysis. The target sequence of APOBEC3B siRNA 1 is 5′-GGU GUAAUUCAAGCCUCAG-3′, and the target sequence of APOBEC3B siRNA 2 is 5′-CCUGAUGGAUCCAGA CACA-3′.

Western blotting
All cells were lysed in 1×SDS lysis buffer (50 mM Tris–HCl, pH 6.8, 2% SDS, 10% glycerol, 1 mM PMSE, and 1 mM Na3VO4) and performed as described previously [18]. A total of 50 μg protein per lane was loaded on an SDS-PAGE gel and transferred to PVDF membrane (Millipore Corporation, USA). After being blocked with PBS containing 5% BSA and 0.05% Tween 20, the membrane was incubated with specific primary antibodies and followed by incubation with HRP-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). The labeled proteins were then visualized by fluorography using an enhanced chemiluminescence system (Thermo Scientific, Pierce Biotechnology, USA).

Sulforhodamine B cell proliferation assay
The Sulforhodamine B (SRB) cell proliferation assay was conducted as previously described [18]. Briefly, 1 × 105 of each four cells were plated in a 6-well plate and transfected with APOBEC3B siRNA or scrambled siRNA. At 24 h post-transfection, cells were seeded in a 96-well plate for the indicated time points and then fixed for 1 h at 4 °C by adding 50 μl of 30% (v/v) trichloroacetic acid. After fixation, the cells were washed five times using distilled water and stained with 100 μl of 0.4% (w/v) SRB in 1% (v/v) acetic acid solution for 30 min at room temperature. The cells were washed five times with 1% acetic acid solution and air-dried. The stain was solubilized in 100 μl of 10 mM Tris (pH 10.5), and the absorbance was measured at 570 nm using a microplate reader (Infinite M200, Tecan, Austria).

Statistical analysis
For patient characteristics, mean and standard deviation (SD) were calculated for continuous variables, and number and percentage were calculated for categorical variables. Survival time was defined as the time from surgery until the patient’s death/recurrence, or the last time that the patient was known to be alive. Kaplan–Meier method was used to estimate the overall survival (OS) and disease-free survival (DFS). Log-rank test was used to compare the curves of different APOBEC3B expression groups. Cox proportional hazards models were used to estimate the survival distributions, hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs). Only significant prognostic variables in univariate analyses were included in the multivariate analyses. Forward Wald test was used in multivariate Cox regression.
models to determine independent prognostic factors. All significance tests were two sided; p value of <0.05 was considered as statistically significant. Data analyses were performed by SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA).

**Results**

**Clinicopathological characteristics and survival of ovarian cancer patients**

In total, 112 ovarian cancer patients who underwent surgery at our hospital were evaluated in this study. TMAs containing ovarian cancer specimens from 112 cases were used. Tissue samples from 24 cases were lost during cutting, leading to 88 ovarian samples for the present study. Table 1 shows the baseline clinicopathological characteristics of the study population. The average age of the patients was 51.42 ± 9.34, with the range of 26–74 years. More than half of the patients had serous ovarian carcinoma (n = 59, 67.0%). The majority of the patients had advanced-stage ovarian cancer (FIGO III and IV: n = 50, 56.8%) at initial diagnosis. After a median observation of 74.77 months (range 1.60–103.13 months), 42 patients had died, 5 had relapsed but were still alive at the end of study, and 41 patients remained alive and were free of ovarian cancer.

**Association of APOBEC3B expression with clinicopathological factors**

Unlike a previous study which reported that APOBEC3B protein predominantly localized to the nuclear compartment in ovarian cancer cell lines [15], our immunostaining data from ovarian cancer tissues showed that APOBEC3B localized in both nuclear and cytoplasmic compartment (Fig. 1). Our immunohistochemistry results also showed that APOBEC3B has a higher ratio of cytoplasmic localization in ovarian cancer tissues (Fig. 1). The association between APOBEC3B expression and clinicopathological variables are presented in Table 2. Briefly, over-expression of APOBEC3B protein was significantly associated with advanced FIGO stage and elevated CA125 (both p< 0.05). There was no significant association between APOBEC3B expression and other clinicopathological factors.

**Association of APOBEC3B expression with survival of ovarian cancer patients**

Patients with APOBEC3B-overexpressing tumors had both worse OS and DFS compared with those without or with lower APOBEC3B-expressing tumors (both p<0.001; Fig. 2a, b). Univariate analyses showed that serous histological subtype (serous vs. non-serous: HR 2.24, 95% CI 1.12–4.47, p = 0.023), higher FIGO stage (III/IV vs. I/II: HR 7.89, 95% CI 3.53–17.60, p < 0.0001),

| Table 1 Clinicopathological characteristics of study patients (n = 88) |
|-----------------------------|-----|-----|
| Variables                   | N   | %   |
| Age at diagnosis (years)    | 51  | 26–74 |
| Age (years)                 |     |     |
| < 50                        | 41  | 46.6 |
| > 50                        | 47  | 53.4 |
| Overall survival (months)   |     |     |
| Median (range)              | 74.77| 1.60–103.13 |
| Number of deaths            | 42  | 47.7 |
| Disease free survival (months) |     |     |
| Median (range)              | 67.65| 0.80–103.13 |
| Number of recurrences       | 46  | 52.3 |
| Menopause                   |     |     |
| Yes                         | 45  | 51.1 |
| No                          | 43  | 48.9 |
| Laterality                  |     |     |
| Right side                  | 23  | 26.1 |
| Left side                   | 16  | 18.2 |
| Bilateral                   | 49  | 55.7 |
| Behavior                    |     |     |
| Borderline                  | 0   | 0   |
| Invasive                    | 88  | 100 |
| Histological subtype (%)    |     |     |
| Serous                      | 59  | 67.0 |
| Non-serous                  | 29  | 33.0 |
| Histological grade (%)      |     |     |
| G1                          | 8   | 9.1 |
| G2                          | 21  | 23.9 |
| G3                          | 37  | 42.0 |
| Missing                     | 22  | 25.0 |
| FIGO (%)                    |     |     |
| I                           | 25  | 28.4 |
| II                          | 13  | 14.8 |
| III                         | 45  | 51.1 |
| IV                          | 5   | 5.7 |
| Intravascular tumor thrombus (%) |     |     |
| Yes                         | 16  | 18.2 |
| No                          | 69  | 78.4 |
| Missing                     | 3   | 3.4 |
| Serum CA 125 (U/mL)         |     |     |
| < 35                        | 11  | 12.5 |
| ≥ 35                        | 63  | 71.6 |
| Missing                     | 14  | 15.9 |
| Serum CA 19-9 (U/mL)        |     |     |
| < 37                        | 38  | 43.2 |
| ≥ 37                        | 18  | 20.5 |
| Missing                     | 32  | 36.4 |
| Serum CEA (ng/mL)           |     |     |
| < 5                         | 58  | 65.9 |
| ≥ 5                         | 2   | 2.3 |
| Missing                     | 28  | 31.8 |
Table 1 (continued)

| Variables                                  | N  | %  |
|--------------------------------------------|----|----|
| Chemotherapy                               |    |    |
| Yes                                        | 83 | 94.3|
| Missing                                    |  5 |  5.7|
| Traditional Chinese medicine treatment     |    |    |
| Yes                                        | 18 | 20.5|
| No                                         | 70 | 79.5|
| APOBEC3B                                   |    |    |
| −                                          |  8 |  9.1|
| +                                          | 32 | 36.4|
| ++                                         | 32 | 36.4|
| +++                                        | 16 | 18.2|

APOBEC3B apolipoprotein B mRNA editing enzyme catalytic subunit 3B, CA 125 cancer antigen 125, CA 19-9 cancer antigen 19-9, CEA carcinoembryonic antigen, FIGO Federation of Gynecologists and Obstetricians

Intravascular tumor thrombus (Yes vs. No: HR 2.27, 95% CI 1.20–4.29, p=0.012), elevated serum cancer antigen (CA) 125 (≥35 U/mL vs. <35 U/mL: HR 5.45, 95% CI 1.32–22.56, p=0.019) and over-expression of APOBEC3B (++++/+ vs. ±: HR 6.34, 95% CI 2.80–14.38, p<0.0001) were significantly associated with a shorter OS (Table 3). Multivariate analysis revealed that higher FIGO stage (III/IV vs. I/II: HR 7.89, 95% CI 2.33–26.70, p=0.001) and higher expression of APOBEC3B (++++/+ vs. ±: HR = 5.18, 95% CI 1.40–11.95, p=0.003) were independent predictive factors of a shorter OS (Table 3). For DFS, serous histological subtype (serous vs. non-serous: HR 2.29, 95% CI 1.18–4.43, p=0.014), higher FIGO stage (III/IV vs. I/II: HR 9.40, 95% CI 4.23–20.86, p<0.0001), intravascular tumor thrombus (Yes vs. No: HR=2.00, 95% CI 1.07–3.75, p=0.030), elevated serum CA125 (≥35 U/mL vs. <35 U/mL: HR 2.00, 95% CI 1.07–3.75, p=0.030) were associated with a shorter DFS (Table 3).
Table 2 Association of APOBEC3B expression with clinicopathological parameters of ovarian cancer

| Variables                        | APOBEC3B | p value |
|----------------------------------|----------|---------|
|                                  | ±        | ++/+++  |
| Age                              |          |         |
| ≤ 50                             | 20       | 21      | 0.558 |
| > 50                             | 20       | 27      |       |
| Histological subtype             |          |         |
| Serous                           | 15       | 14      | 0.408 |
| Non-serous                       | 25       | 34      |       |
| FIGO stage                       |          |         |
| I/II                             | 25       | 13      | 0.001 |
| III/IV                           | 15       | 35      |       |
| Histological grade*              |          |         |
| G1                               | 4        | 4       | 0.976 |
| G2                               | 10       | 11      |       |
| G3                               | 17       | 20      |       |
| Intravascular tumor thrombusa    |          |         |
| No                               | 33       | 36      | 0.455 |
| Yes                              | 6        | 10      |       |
| CA 125b                          |          |         |
| < 35 U/mL                        | 9        | 2       | 0.004 |
| ≥ 35 U/mL                        | 22       | 41      |       |

CA 125 cancer antigen 125, FIGO Federation of Gynecologists and Obstetricians
* Number of missing value = 22
a Number of missing value = 3
b Number of missing value = 14

Effects of APOBEC3B expression on the viability of ovarian tumor cells

As APOBEC3B has been indicated in cancer progression [10], we then observed whether APOBEC3B promoted cell viability of human ovarian cancer cells. Four ovarian cancer cell lines with different endogenous expression of APOBEC3B were chosen. It has been shown that the expression of APOBEC3B in SKOV3 and HEY cells was lower, while the expression of APOBEC3B in A2780 and HO-8910PM was higher [15]. As shown in Fig. 3a, b, APOBEC3B siRNA caused a dramatic decrease in APOBEC3B expression in human A2780 and HO-8910PM ovarian cancer cells and knocking-down of APOBEC3B resulted in a modest decrease in cell viability. However, pLenti-APOBEC3B transfection could not improve cell viability of SKOV3 and HEY cells (Fig. 3c, d). Presumably, APOBEC3B over-expression could not improve cell viability directly but it may be crucial for the maintenance of cell viability.

![Fig. 2](image-url)  
Fig. 2 Kaplan-Meier survival curve. a Overall survival; b Disease-free survival stratified by APOBEC3B expression in 88 ovarian cancer patients
Discussion

Our study results showed that APOBEC3B expression was one of the independent prognostic factors to predict OS and DFS of ovarian cancer patients. In addition, the in vitro data from our study showed that knock-down of APOBEC3B expression affected ovarian cancer cell viability. Taken together, our study indicated that APOBEC3B expression may play an important role in viability and survival of ovarian cancer.

Ovarian cancer is a heterogeneous disease with a high degree of genomic instability, pro-/anti-tumor immunity and inflammation, and remains to be the most lethal gynecologic cancer [19]. Survival outcomes are also far from satisfactory, about 70% of patients diagnosed with advanced-stage ovarian cancer will suffer from recurrence due to high chemotherapy resistance or therapeutic failure [20]. It is of immense importance to identify biomarkers that can predict the prognosis of ovarian cancer patients, as well as help direct the use of tailored therapies.

APOBEC mutation pattern was identified in several cancer types including breast, bladder, cervical, head and neck and lung cancers. APOBEC family members can target host genomic DNA, generating signature mutation clusters in the genome. It is reported that the APOBEC-mediated mutagenesis was correlated with APOBEC mRNA levels, particularly with APOBEC3B [10, 11]. APOBEC3B is hypothesized to be the principal cancer driver of A3-catalyzed somatic mutations, and plays a prominent role in the genesis and evolution of various cancers. As part of the innate immune system, which plays a key role in combating exogenous infection especially viral infection, APOBEC3B expression is stimulated by a complex network of innate immune responses involving components such as interferons, interleukins, and Toll-like receptors [7]. APOBEC3B can cause C-to-T transition in carcinogenesis [21].

Studies have shown that APOBEC3B expression is elevated in a variety of cancer tissues and cell lines, compared to the low levels in the corresponding normal human tissues [10, 21, 22]. In the genome of cervical cancer patients, APOBEC3B protein over-expression was correlated with the enrichment of APOBEC3B mutation signature [11]. What’s more, in vitro study showed estrogen can directly activate AID mRNA expression in an ovarian cancer cell line [23]. As for ovarian cancer, study has shown that high APOBEC3B expression correlates with C-to-A and C-to-G transversion mutations within 5′-TC dinucleotide motifs in the genomes of early-stage high-grade serous ovarian cancer, indicating APOBEC3B may play a role in serous ovarian cancer genomic instability [15]. Studies have reported that higher levels of APOBEC3B expression is associated with decreased survival rates among estrogen receptor-positive (ER+) breast cancer patients [12, 24]. Furthermore, elevated APOBEC3B expression is correlated with a declined efficacy of tamoxifen (TAM) therapy in recurrent ER+ breast cancer patients [25]. In consistent with previous studies, our multivariate results showed that higher expression of APOBEC3B was independently associated with worse survival of ovarian cancer patients. Because of its tumorigenic role in promoting mutational processes, APOBEC3B has clinical potential to serve as novel therapeutic target. It is likely that chemical probes and therapeutic molecules targeting APOBEC3B, when used in combination with existing cancer therapies, will slow or possibly prevent metastasis, development of drug resistance, and therapy failure in human cancers [26].

Table 3 Univariate and multivariate analyses of factors associated with overall survival

| Variables                        | Overall survival | Disease-free survival |
|----------------------------------|------------------|-----------------------|
|                                  | HR (95% CI)      | p value               | HR (95% CI)      | p value               |
| Univariate analyses              |                  |                       |                  |                       |
| Age (> 50 vs. ≤ 50)              | 1.10 (0.63–1.91) | 0.734                 | 1.18 (0.70–2.00) | 0.537                 |
| Histological subtype (serous vs. non-serous) | 2.24 (1.12–4.47) | 0.023                 | 2.29 (1.18–4.43) | 0.014                 |
| FIGO stage (III/IV vs. I/II)     | 7.89 (3.53–17.60) | <0.0001               | 9.40 (4.23–20.86) | <0.0001               |
| Histological grade (G2/G3 vs. G1) | 1.36 (0.72, 2.54) | 0.341                 | 1.44 (0.79–2.63) | 0.239                 |
| Intravascular tumor thrombus (Yes vs. No) | 2.27 (1.20–4.29) | 0.012                 | 2.00 (1.07–3.75) | 0.030                 |
| CA 125 (≥ 35 U/mL vs. < 35 U/mL) | 5.45 (1.30–22.56) | 0.019                 | 5.90 (1.40–24.32) | 0.014                 |
| APOBEC3B (+++/+ vs. ±)           | 6.34 (2.80–14.38) | <0.0001               | 5.18 (2.40–10.80) | <0.0001               |
| Multivariate analyses            |                  |                       |                  |                       |
| FIGO stage (III/IV vs. I/II)     | 7.89 (2.33–26.70) | 0.001                 | 9.75 (2.89–32.90) | <0.0001               |
| APOBEC3B (+++/+ vs. ±)           | 5.18 (1.40–11.95) | 0.003                 | 4.23 (1.60–11.17) | 0.004                 |

CA 125 cancer antigen 125, FIGO Federation of Gynecologists and Obstetricians, HR hazard ratio, 95% CI 95% confidence interval.
has been well established that APOBEC3B is a molecular driver of mutagenesis in various human cancers [22].

![Fig. 3](image)

**Fig. 3** The effects of APOBEC3B on cell viability at different time point (24 hr, 48 hr, and 72 hr) of ovarian cancer cell lines. **a** and **b** A2780 and HO-8910PM cells were transfected with scrambled siRNA, APOBEC3B siRNA 1 or APOBEC3B siRNA 2, cell viability and APOBEC3B expression were detected by SRB assay (the upper panels) and western blotting analysis (the lower panels), respectively. **c** and **d** SKOV3 and HEY cells were transfected with Vector or pLenti-APOBEC3B, cell viability and APOBEC3B expression were detected by SRB assay (the upper panels) and western blotting analysis (the lower panels), respectively. Data are presented as mean ± SEM (n = 3) *p < 0.05, compared with control cells. A representative blot of triplicate blots is shown. GAPDH was used as the loading control.

Its aberrant expression leads to unexpected clusters of mutations in the majority of cancers [22].
In conclusion, our study showed that over-expression of APOBEC3B is associated with the development of new ovarian cancer treatment strategies.

Abbreviations

APOBEC3B: apolipoprotein B mRNA editing enzyme catalytic subunit 3B; ATCC: American Type Culture Collection; CA 125: cancer antigen 125; DFS: disease-free survival; ESR+ : estrogen receptor-positive; FIGO: Federation of Gynecologists and Obstetricians; HE: hematoxylin and eosin; HR: hazard ratios; HRP: horseradish peroxidase; OS: overall survival; SD: standard deviation; SRB: Sulforhodamine B; TAM: tamoxifen; TMA: tissue microarray; 95% CI: 95% confidence interval.

Authors’ contributions

YD analyzed data and wrote the manuscript; XT performed the TMA construction and Immunohistochemistry; JW, HY, and YY performed the cell line experiments; HZ conceived, designed and supervised the study. All authors read and approved the final manuscript.

Conclusions

In conclusion, our study showed that over-expression of APOBEC3B is associated with the development and prognosis of ovarian cancer patients, possibly through influencing viability of ovarian cancer. Therefore, APOBEC3B is a potential therapeutic target which may contribute to the development of new ovarian cancer treatment strategies.
12. Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer. 2014;5:405–13.

13. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013;45:977–83.

14. Svoboda M, Meshcheryakov A, Heinze G, Jaritz M, Pilis D, Castillo-Tong DC, et al. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. BMC Genomics. 2016;17:643.

15. Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013;73:7222–31.

16. Chang W, Gao X, Han Y, Du Y, Liu Q, Wang L, et al. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. Gut. 2014;63:1457–67.

17. Gao XH, Liu QZ, Chang W, Xu XD, Du Y, Han Y, et al. Expression of ZNF148 in different developing stages of colorectal cancer and its prognostic value: a large Chinese study based on tissue microarray. Cancer. 2013;119:2212–22.

18. Zhao HB, Tang CL, Hou YL, Xue LR, Li MQ, Du MR, et al. CXCL12/CXCR4 axis triggers the activation of EGF receptor and ERK signaling pathway in CsA-induced proliferation of human trophoblast cells. PLoS ONE. 2012;7:e38375.

19. Dao F, Schlappé BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016;141:260–3.

20. Muggia FM, Brady PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18:106–15.

21. Rebhandl S, Huerer M, Gassner FJ, Zabonsky N, Hebenstreit D, Catakovic K, et al. APOBEC3 signature mutations in chronic lymphocytic leukemia. Leukemia. 2014;28:1929–32.

22. Zou J, Wang C, Ma X, Wang E, Peng G. APOBEC3B, a molecular driver of mutagenesis in human cancers. Cell Biosci. 2017;7:29.

23. Pauklin S, Sernandez IV, Bachmann G, Ramiro AR, Petersen-Mahrt SK. Estrogen directly activates AID transcription and function. J Exp Med. 2009;206:99–111.

24. Cescon DW, Hapae-Kains B, Mak TW. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci USA. 2015;112:2841–6.

25. Law EK, Sieuwerts AM, Lapaia K, Leonard B, Starrett GJ, Molan AM, et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv. 2016;2:e1601737.

26. Olson ME, Harris RS, Harki DA. APOBEC enzymes as targets for virus and cancer therapy. Cell Chem Biol. 2018;25:36–49.